CERo Therapeutics Holdings, Inc. develops cellular immunotherapy candidates for cancer using engineered T cells that employ phagocytic mechanisms. Company news centers on its CER-T platform, the lead product candidate CER-1236, and clinical updates from the CERTAIN-T Phase 1 trial in hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndromes, and myelofibrosis.
Recurring updates also address safety monitoring, pharmacokinetic and pharmacodynamic observations, dose-escalation cohorts, scientific presentations, board composition, financing activity, and trading or listing-status developments for CERO common stock and warrants.
CERo Therapeutics (CERO) activated the University of California, Davis as a clinical site for its ongoing Phase 1 CERTAIN-T trial of CER-1236.
UC Davis also serves as the primary manufacturing site. CERo expects activation to expand recruitment capacity and streamline treatment logistics. Previously reported findings covered six patients in two cohorts. All three second-cohort patients completed the 28-day dose-limiting toxicity assessment without a dose-limiting toxicity. Preliminary investigator observations noted clinical improvement in two patients, but formal response assessments remain ongoing and no definitive safety or efficacy conclusions can be drawn. One patient with refractory acute myeloid leukemia subsequently underwent donor stem cell transplantation 71 days after infusion. The protocol was amended to include myelodysplastic syndromes and myelofibrosis.
CERo Therapeutics (CERO) has activated Fred Hutch Cancer Center in Seattle as an additional site for its Phase 1 CERTAIN-T trial. The trial evaluates CER-1236 in hematological cancers, with Jacob Appelbaum serving as principal investigator at Fred Hutch.
Previously reported findings covered six patients in two cohorts. All three second-cohort patients completed the 28-day assessment without dose-limiting toxicity. A June 2026 update reported no cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, dose-limiting toxicities or treatment-related severe adverse events during that assessment window. Preliminary investigator observations noted clinical improvement in two patients, but formal response assessments remain ongoing and no definitive safety or efficacy conclusions can be drawn. The protocol has also been amended to include MDS and myelofibrosis.
CERo Therapeutics (OTCQB:CERO) reported a Phase 1 update from the CERTAIN-T trial of CER-1236 in hematologic malignancies. The fifth patient, with refractory AML, showed bone marrow blasts of 14% on Days 14 and 28 and 7% on Day 42 after treatment and subsequently underwent allogeneic stem cell transplant on Day 71.
CERo has treated six patients to date. Across cohorts, investigators have reported no CRS, ICANS, dose-limiting toxicities or treatment-related severe adverse events during the DLT window. The company has opened the third cohort, expected to test a one billion cells/patient protocol and include MDS and MF patients. All data are preliminary and not yet sufficient to determine safety or efficacy.
CERo Therapeutics (OTCQB:CERO) completed the second ascending-dose cohort in its Phase 1 CERTAIN-T trial of CER-1236 for hematologic malignancies. Three patients received 4 × 10⁶ cells/kg with no dose-limiting toxicities, supporting escalation to 1 × 10⁷ cells/kg.
The trial has now treated six patients and will expand to include myelodysplastic syndrome and myelofibrosis patients.
CERo Therapeutics (OTCQB: CERO) dosed the third patient in Cohort 2 (sixth patient overall) of the Phase 1 CER-1236 trial in hematologic malignancies on April 14, 2026. The study was expanded to include transfusion-dependent and high-risk MDS and post-JAK inhibitor myelofibrosis.
Key clinical observations include no reported CRS or ICANS, no dose-limiting toxicities in the 28-day window, observed in vivo cell expansion (peaks days 10–14), and one patient achieving 72 days of platelet transfusion independence after repeated infusions.
CERo Therapeutics (OTCQB: CERO) dosed the second patient in Cohort 2 (fifth overall) of its Phase 1 CER-1236 trial on March 30, 2026, advancing safety, PK/PD and activity monitoring in AML with planned expansion into MDS and MF.
The company reported no CRS or ICANS, no dose‑limiting toxicities in the 28‑day window, in vivo T cell expansion peaking days 10–14, and a single patient with 72 days of platelet transfusion independence; enrollment was amended to include TD‑MDS, HR‑MDS, and post‑JAK‑inhibitor MF.
CERo Therapeutics (OTCQB: CERO) provided a shareholder update on March 11, 2026 describing clinical, financing, governance, and strategic progress. Key points: early clinical activity for lead candidate CER-1236 (20–70x cell expansion; one MDS patient with >56-day platelet transfusion independence), convertible debt funding to sustain operations, engagement of an investment bank to pursue a Nasdaq relisting, and the appointment of Eric Francois to the board.
CERo Therapeutics (OTCQB: CERO) appointed industry veteran Eric Francois to its Board of Directors effective Feb 17, 2026. Francois brings over 25 years in life sciences finance, including 18 years as a senior banker and prior service as CFO who helped raise over $300M.
The company highlighted his strengths in capital raising, M&A and business development to support CERo's cellular immunotherapy programs and ongoing human clinical trial.
CERo Therapeutics (OTCQB:CERO) will present interim Phase 1 CERTAIN-T data at ASTCT/CIBMTR on February 5, 2026. Key findings include approximately 20–70-fold in vivo cell expansion peaking days 7–14, no dose-limiting toxicities in first four patients, and an index AML/MDS patient achieving platelet transfusion independence >56 days. The trial has been amended to include transfusion-dependent MDS, high-risk MDS, and post-JAK-inhibitor myelofibrosis; cohort 2 enrollment is underway.
CERo Therapeutics (OTCQB: CERO) provided a Phase 1 CertainT-1 clinical update for CER-1236 in AML on January 7, 2026.
Key points: investigators observed cell expansion with no CRS, ICANS, or treatment-related adverse events to date; a patient with MDS that progressed to AML had a 61-day platelet transfusion–free interval, exceeding an 8-week benchmark; transfusion independence ended after a later round of lymphodepleting chemotherapy plus CER-1236. The company filed an amendment with the FDA to add advanced MDS and myelofibrosis cohorts and will host an analyst call on Jan 7, 2026 at 5:00 PM ET.